☰

Biotts S.A.

Connecting laboratory and manufacturing data across two sites

Industry
Transdermal Drug Delivery and CDMO Services
Headquarters
Wroclaw, Poland (with Boston, United States)
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Biotts S.A.'s published strategy and is not endorsed by, or produced in cooperation with, Biotts S.A.. Company website

Strategic priorities

Biotts S.A. develops the MTC-Y (Multifunctional Transdermal Carrier Y) platform, a non-invasive delivery system that has demonstrated transport of molecules up to 6,000 Da across the skin in preclinical and Phase 1 studies. The company's lead programme, MTC-INS, is a five-day insulin patch developed with Bioton S.A. and targeted for clinical entry in 2025 and market readiness by 2027, building on the MTC-D dapagliflozin Phase 1 success in 30 healthy volunteers and the MTC-S1 semaglutide preclinical work.

The Wroclaw facility operates as a GMP-certified analytical and clinical-batch site equipped with HPLC, UPLC, LC-MS/MS, Franz diffusion cells and ICH-compliant stability chambers, while the Boston office anchors commercial and partnership work. Together the two sites must move formulation data, bioanalytical results, and CMC (Chemistry, Manufacturing and Controls) documentation into a single regulatory-grade evidence chain for the FDA and EMA submissions planned for 2027.

Financial context sets the timeline. Net sales fell 46.25 percent in 2024 during a wider biotech retrenchment, while total assets grew 21.82 percent over the same period. With venture funding in the sector up 70.9 percent in Q3 2025, the path through Phase 1 for the insulin patch and parallel regulatory submissions is a multi-year execution problem where the laboratory and manufacturing data systems either enable the timeline or hold it back.

Challenges we see

  • Compliance Regulatory

    Defining the regulatory framework for transdermal macromolecules

    Fewer than 30 drugs have reached FDA approval for transdermal delivery to date and almost all are small molecules. Biotts is moving molecules up to 6,000 Da, including insulin and GLP-1 receptor agonists, through a delivery route with no standardised analytical parameters, working with both the FDA and EMA in parallel.

    Where the regulatory category itself is being defined, the working assumption has to be that clinical evidence and bioanalytical data arrive in formats both agencies can re-use, rather than in formats assembled once for one submission and rebuilt for the next.

  • Operations Manufacturing

    Scaling GMP manufacturing from preclinical to clinical batches

    The Wroclaw facility currently supports clinical batch production for small-scale prototypes, capsules, tablets, liquids and patches. Moving from 55 percent bioavailability in animal models to commercial-scale five-day insulin patches requires capacity expansion, process validation and consistent adhesion and stability performance across batches.

    As batch volumes grow and the carrier must perform identically from one run to the next, the practical shift is from proving the formulation works in small studies to running the same process with the same controls at larger scale, with the evidence generated by the line rather than reconstructed after the fact.

  • Digital Integration

    Maintaining data integrity across Wroclaw and Boston

    R&D is split between Wroclaw (laboratory, GMP manufacturing) and Boston (commercial, partnership). LIMS (Laboratory Information Management System) and ELN (Electronic Laboratory Notebook) platforms are in place, but consistent data flows and FDA 21 CFR Part 11 compliance across both sites require integration architecture that supports real-time collaboration.

    Where experiments happen on one site and commercial decisions happen on another, the working question is whether a result entered in Wroclaw is readable in Boston without manual re-formatting, so collaboration time is spent on interpretation rather than reconciliation.

  • Operations Integration

    Validating bioanalytical methods across a wide molecular weight range

    Pharmacokinetic studies use LC-MS/MS at nanogram concentrations to quantify drug in blood and skin for molecules ranging from 500 Da to 6,000 Da, with method validation required against ICH Q2 standards across the full therapeutic pipeline.

    When the same laboratory must validate methods for molecules of very different size and physicochemistry, the practical case for shared instrument calibration data, method-versioning and result-comparison tooling becomes the difference between a method being transferable and a method being rebuilt each time.

  • Operations Finance

    Sustaining capital runway through the 2027 submission target

    Net sales fell 46.25 percent in 2024 alongside a 21.82 percent rise in total assets, and the MTC-INS Phase 1 entry planned for early 2025 sits ahead of the market readiness target for 2027. The wider biotech sector saw venture funding grow 70.9 percent in Q3 2025 against Q2.

    When funding is recovering but a multi-year clinical and regulatory path still has to be financed, the operational priority is to demonstrate repeatable technical progress in a way investors and partners can verify, so each clinical milestone is reached with capital still in place.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Predicting skin permeability from molecular properties

    Transdermal formulation optimization requires iteration across excipient combinations, API (Active Pharmaceutical Ingredient) concentrations and permeation testing, with manual workflows extending development timelines for each new MTC-Y carrier variation.

    Models trained on historical permeation, molecular weight, LogP (a measure of a molecule's fat-solubility) and hydrogen-bonding data can rank candidate formulations before wet-lab work, so the experiments that get run are the ones the model already favours.

    • Biotts, R&D and Laboratory Services
    • Biotts, Technology

  2. Unifying laboratory informatics across both sites

    The Wroclaw facility operates HPLC, UPLC, LC-MS/MS, Franz diffusion cells and stability chambers whose data is integrated into LIMS and ELN by hand, slowing cross-site work with Boston and creating compliance risk for submissions that scrutinise data provenance.

    Direct equipment connectivity to a shared LIMS/ELN layer captures results with instrument identity, method version and timestamp attached, so records arriving in either office carry the same audit trail without re-keying.

    • Biotts, R&D and Laboratory Services
    • Biotts, Audacious Impact interview, Medium 2025

  3. Producing CMC documentation from the line rather than after it

    GMP manufacturing of transdermal patches and ointments requires Chemistry, Manufacturing and Controls (CMC) documentation that demonstrates batch-to-batch consistency in adhesion, stability and permeation, assembled today by hand.

    Electronic batch records with embedded process controls write monitored parameters into a per-batch record with lineage to the instrument that produced each value, so the evidence behind a release decision is generated continuously rather than compiled at the end.

    • Biotts, R&D and Laboratory Services
    • FDA CMC requirements for transdermal systems, FDA guidance

  4. Modelling permeation data alongside molecular properties

    Franz diffusion cell studies and artificial-membrane permeation assays generate critical transdermal flux data that sits in isolated files and instrument logs, limiting trend analysis and cross-experiment comparisons during carrier optimisation.

    A semantic data model linking permeation performance to physicochemical descriptors lets current and historical runs be compared on the same terms, so optimisation work uses the whole experimental record rather than the last few results.

    • Biotts, R&D and Laboratory Services
    • Biotts, Technology

  5. Producing regulatory submissions and technical documentation for partners

    As formulations move from R&D into GMP and into licensing discussions with larger pharmaceutical companies, the technical documentation that travels with them is assembled from paper records, instrument logs and informal notes.

    Structured documentation generated from the underlying system records, with a named reviewer signing each output, gives partners and regulators a single coherent package to evaluate rather than a pile of supporting evidence.

    • Biotts, Audacious Impact interview, Medium 2025
    • Leonarto VC, Biotts–Bioton strategic partnership announcement

What we'd propose

  • Digital Lab

    Predictive screening for transdermal formulation candidates

    A machine-learning layer over Biotts's existing permeation and molecular-property data that ranks new candidate formulations by predicted skin permeability before any wet-lab work, so the experiments the team runs are the ones the model already favours.

    • Permeability prediction from molecular descriptors

      Ranking formulations before synthesis

      Train models on Biotts's historical Franz-cell, PAMPA (Parallel Artificial Membrane Permeability Assay) and skin-model data together with molecular weight, LogP and hydrogen-bonding descriptors, so new candidates arrive at the bench with a predicted transdermal flux and a confidence range.

    • Excipient optimisation from historical runs

      Carrier composition grounded in data

      Use past formulation data to identify excipient ratios that have worked for specific API (Active Pharmaceutical Ingredient) classes, so the iteration loops for new therapeutic candidates start from the best-known composition rather than from a blank page.

    • Candidate screening dashboard

      Visible go/no-go at the bench

      Surface predicted performance, confidence and supporting evidence for each formulation in a single view, so researchers can decide what to make next without leaving the workflow they already use.

    • Fewer wet-lab iterations per candidate reach the same go/no-go confidence.
    • Each new API class starts from the best-known carrier composition rather than from scratch.
    • Researchers spend their time on the experiments the model already favours.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Unified LIMS/ELN across Wroclaw and Boston

    An integrated LIMS/ELN layer that connects Biotts's analytical instruments to a shared record, so results captured in Wroclaw are readable in Boston without re-keying and the audit trail holds under FDA 21 CFR Part 11 review.

    • Direct instrument connectivity

      Results captured at the instrument

      Connect HPLC, UPLC, LC-MS/MS, Franz diffusion cells and stability chambers through OPC UA (Open Platform Communications Unified Architecture) or vendor protocols so result files carry instrument identity, method version and timestamp from the moment they are written.

    • Cross-site ELN workflow

      One notebook, two sites

      Implement an ELN layer shared between Wroclaw and Boston, with role-based access and a single sample and result model, so an experiment written in Wroclaw is referenced from Boston in the same terms.

    • 21 CFR Part 11 audit trail

      Records that hold under inspection

      Apply electronic signature, versioning and audit-trail handling to 21 CFR Part 11, the US rule on electronic records and signatures, and to EU Annex 11, so the evidence chain is generated by the systems rather than assembled for review.

    • Cross-site work stops spending time on reconciliation and starts spending it on interpretation.
    • Records arrive at the regulator already carrying the audit trail the inspector expects.
    • New instruments attach to the shared data path rather than triggering another integration.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Electronic batch records and CMC documentation for transdermal manufacturing

    An electronic batch record and CMC documentation system for Biotts's GMP clinical-batch manufacturing, with embedded process controls that produce the regulatory evidence chain as the line runs rather than after the batch ships.

    • Electronic batch record engine

      Batch records that write themselves

      Replace paper-based batch records with guided electronic workflows that enforce process steps, capture in-line measurements and prevent unauthorised deviations during clinical-batch production of patches and ointments.

    • CMC document assembly

      CMC sections generated from the data

      Extract manufacturing data, stability results and process parameters into regulatory-compliant CMC sections, so IND (Investigational New Drug) and NDA (New Drug Application) preparation time falls and the same evidence is available to both the FDA and EMA submissions.

    • Deviation and CAPA tracking

      Quality events caught while they happen

      Implement automated deviation detection, root-cause analysis workflows and CAPA (Corrective and Preventive Action) tracking so batch quality is demonstrated to regulators from the live record rather than reconstructed at submission time.

    • CMC documentation arrives at submission time already assembled from the manufacturing record.
    • Adhesion, stability and permeation performance are demonstrated by the data the line produces.
    • Deviations are tracked from the moment they occur, with the corrective action attached to the same record.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Semantic data platform for permeation and molecular data

    A data platform with a shared semantic model that contextualises Franz-cell and PAMPA permeation data alongside molecular properties, enabling cross-experiment analytics across the entire MTC-Y formulation history.

    • Permeation data pipeline

      Diffusion data in one place

      Automatically capture Franz-cell flux measurements, PAMPA results and skin-model data into a centralised repository with a standardised schema, so permeation results are queryable rather than locked inside individual experiment files.

    • Molecular property ontology

      Performance and properties linked

      Implement ontology-based modelling that links permeation performance to physicochemical descriptors, so the relationship between carrier composition, API class and skin flux can be analysed across the entire experimental record.

    • Cross-experiment comparison

      History in front of every result

      Enable overlay of current formulation data against historical best-performing compositions, so each new candidate is benchmarked against the proven winners before it advances to the next stage.

    • Each new experiment is benchmarked against the entire permeation history, not the last few runs.
    • Carrier optimisation decisions are grounded in data the team can query, not just in the most recent result.
    • Future therapeutic programmes inherit the same data foundation instead of starting from empty files.

    We've done this before

    See how we do Enterprise AI
  • Agents

    AI agents for regulatory submissions and partnership documentation

    Narrow, reviewable agents that take the repetitive part of Biotts's documentation work: drafting CMC and IND sections from source records, checking submissions against the regulator's template, and tracing the documents a change to the carrier or process touches. A named person approves each output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of CMC sections, IND summaries and partnership documentation directly from the underlying LIMS, ELN and batch record data, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before submission

      Check a draft against the FDA and EMA submission templates and against Biotts's own quality checklist, returning missing or inconsistent sections before the document enters human review.

    • Change impact search across the document set

      What a formulation change touches

      When the carrier composition, manufacturing process or a regulatory standard changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Submission drafts arrive at review already carrying the data behind them.
    • Partnership documentation is generated from the same evidence chain regulators see.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Biotts S.A.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Laboratory informatics 55 → 85
LIMS and ELN platforms are deployed at the Wroclaw site but instrument integration and cross-site data sharing are partial. The Phase 1 and 2027 submission timelines make a single regulatory-grade record across both sites a near-term requirement.
Data analytics 45 → 80
Permeation analysis today is largely Excel-based and anchored to the most recent experiment. Predictive models over historical Franz-cell and molecular-property data would make formulation decisions data-led rather than run-led.
Manufacturing digitisation 50 → 85
The GMP facility has quality instrumentation in place but paper-based batch records and CMC documentation are still assembled by hand. Moving to electronic batch records is on the critical path for the 2027 submission target.
IT/OT integration 40 → 75
Analytical and permeation equipment produces valuable data but mostly in vendor-specific formats, and instrument connectivity is partial. Shared protocol layers would make results queryable across the laboratory estate.
Process automation 35 → 70
Formulation development and permeation testing are still largely manual. Even a partial move to automated screening and shared run records would compress the iteration cycle for new MTC-Y variants.
Knowledge management 45 → 80
Collaboration between Wroclaw and Boston runs through informal channels and the most recent experiment rather than a structured knowledge layer. A unified record of formulations, results and decisions would let each site build on the other's work.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Biotts S.A., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].